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Background: It has been previously shown that biosimilar inﬂiximab CT-P13 is effective and safe in inducing remission in inﬂammatory bowel
diseases.
Aim: We report here the 1-year outcomes from a prospective nationwide inﬂammatory bowel disease cohort.AU3
Methods: A prospective, nationwide, multicenter, observational cohort was designed to examine the efﬁcacy and safety of CT-P13 in the induction and
maintenance treatment of Crohn’s disease (CD) and ulcerative colitis (UC). Demographic data were collected and a harmonized monitoring strategy was
applied. Clinical remission, response, and biochemical response were evaluated at weeks 14, 30, and 54, respectively. Safety data were registered.
Results: Three hundred ﬁfty-three consecutive inﬂammatory bowel disease (209 CD and 144 UC) patients were included, of which 229 patients reached
the week 54 endpoint at ﬁnal evaluation. Age at disease onset: 24/28 years (median, interquartile range: 19–34/22–39) in patients with CD/UC. Forty-
nine, 53, 48% and 86, 81 and 65% of patients with CD reached clinical remission and response by weeks 14, 30, and 54, respectively. Clinical remission
and response rates were 56, 41, 43% and 74, 66, 50% in patients with UC. Clinical efﬁcacy was inﬂuenced by previous anti–tumor necrosis factor (TNF)
exposure in patients with a drug holiday beyond 1 year. The mean C-reactive protein level decreased signiﬁcantly in both CD and UC by week 14 and
was maintained throughout the 1-year follow-up (both UC/CD: P , 0.001). Thirty-one (8.8%) patients had infusion reactions and 32 (9%) patients had
infections. Antidrug antibody positivity rates were signiﬁcantly higher throughout patients with previous anti-TNF exposure; concomitant azathioprine
prevented antidrug antibody formation in anti–TNF-naive patients with CD .
Conclusions: Results from this prospective nationwide cohort conﬁrm that CT-P13 is effective and safe in inducing and maintaining long-term
remission in both CD and UC. Efﬁcacy was inﬂuenced by previous anti-TNF exposure; no new safety signals were detected.
(Inﬂamm Bowel Dis 2017;00:1–8)
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B iosimilar inﬂiximab (IFX) CT-P13 was approved by theEuropean Medicines Agency (EMA) in September 2013
and by the U.S. Food and Drug Administration (U.S. FDA) in
April 2016 for all indications of the originator product.1,2 The
extrapolation of the use of biosimilar IFX in inﬂammatory bowel
diseases (IBDs) was based on the results from 2 randomized
controlled trials conducted in ankylosing spondylitis and rheuma-
toid arthritis, which demonstrated similarity in pharmacokinetics
and clinical efﬁcacy between the biosimilar IFX and the originator
product.3,4 Since May 2014, the use of biosimilar IFX is manda-
tory in Hungary in all anti–tumor necrosis factor (TNF)-naive
patients and in patients who were previously treated with the
originator product with a proven clinical beneﬁt but have been
on drug holiday for longer than 12 months.
The efﬁcacy and safety of biosimilar IFX in IBD have been
studied in the past 2 years, and real-life cohorts show comparable
outcomes as in patients treated with the originator IFX.5–14 As
previously reported in the prospective, nationwide, multicenter
study by our study group published in 2016 including 210 patients
with IBD, high response and remission rates throughout 30 weeks
were found in both Crohn’s disease (CD) and ulcerative colitis
(UC).7 At week 30, 67.2% and 53.4% of patients with CD showed
clinical response or clinical remission, whereas clinical response
or remission was demonstrated in 80% and 68% of patients with
UC. Early efﬁcacy was affected by previous anti-TNF exposure
with no new signal in adverse events.
In this study, our aim was to evaluate the medium- and
long-term efﬁcacy, safety, and immunogenicity of biosimilar IFX
CT-P13 (Inﬂectra) in a Hungarian consecutive, nationwide cohort
of patients with IBD treated up to 54 weeks.
MATERIALS AND METHODS
This study is a multicenter, nationwide prospective obser-
vational study. Eligible patients older than 18 years started on
biosimilar IFX therapy were consecutively enrolled. The inclusion
started in May 2014 in 12 IBD centers in Hungary.
A harmonized monitoring strategy was applied in all
participating centers, as requested by the National Health Fund.
Patient demographics, previous, and concomitant medications
were collected, and biochemical and clinical assessment was
performed at start and every 3 months thereafter. Disease location
and behavior in CD and disease extent in UC were assessed
according to the Montreal classiﬁcation.15 Patients were either
naive to anti-TNF or had response to previous anti-TNF therapy
but were stopped because of nonmedical reasons with a drug
holiday beyond 1 year. A more detailed description of the meth-
odology and case ascertainment of the cohort was published
previously.7
Patients received intravenous infusions of the biosimilar
IFX CT-P13 at a dose of 5 mg/kg of body weight at weeks 0, 2,
and 6, and then every 8 weeks. Only patients with a clinical
response at week 14 were eligible for maintenance therapy.
Clinical response, remission, biochemical response,
immunogenicity, and safety were evaluated at weeks 14, 30,
and 54. Patients lost to follow-up or with missing data were
regarded as nonresponders.
Clinical remission was deﬁned as a Crohn’s Disease Activity
Index (CDAI) ,150 points or no ﬁstula drainage as assessed by the
Fistula Drainage Assessment in CD, and as a partial Mayo (pMayo)
score of less than 3 points in UC.16–18 Clinical response was deﬁned
as a decrease in CDAI with more than 70 points and/or at least 50%
reduction in the number of draining ﬁstulas in CD, and a decrease in
the pMayo score with more than 3 points in UC. Biochemical activ-
ity was evaluated by measuring total blood count, serum C-reactive
protein (CRP, normal cut-off: 10 mg/L), and albumin.
For the measurement of biosimilar IFX trough level (TL)
and antidrug antibody (ADA), a conventional and bridging
enzyme-linked immunosorbent assay was used (LISA
TRACKER; Theradiag, France, United Kingdom). The kit was
formally validated for the use in patients treated with the
biosimilar IFX before commencing on the study. All sample
measurements were performed at the Department of Laboratory
Medicine, Semmelweis University, Budapest. The enzyme-linked
immunosorbent assay kit was validated for accuracy and repro-
ducibility of therapeutic drug level monitoring of the biosimilar
IFX (Theradiag). The detection cut-off value of biosimilar IFX TL
was 0.1 mg/mL, whereas 3 to 7 mg/mL was deﬁned as therapeu-
tic.19,20 For ADA level, the standard cut-off value was 10 ng/mL.
Ethical Considerations
Ethical approval was acquired from the National Ethical
Committee 929772-2/2014/EKU (292/2014). The study was regis-
tered at the EMA European Network of Centres for Pharmacoe-
pidemiology and Pharmacovigilance (ENCEPP/SDPP/9053).
Written informed consent was obtained from all participants.
Statistical Analysis
For the characterization of patients’ demographic data,
remission and response rates at weeks 14, 30, and 54, and adverse
events, descriptive statistics were applied. Medians and interquar-
tile ranges were calculated for continuous variables. For the com-
parison of clinical response, remission rates, and ADA positivity
rates between anti–TNF-exposed and naive patients, chi2 test or
Fisher’s exact test was used. For the comparison of mean CRP
levels at weeks 14, 30, and 54, the paired-sample T test was used.
Statistical analysis was performed using SPSS software v. 20.0
(Chicago, IL); P ,0.05 was considered statistically signiﬁcant.
RESULTS
A total of 353 consecutive IBD (209 CD and 144 UC)
patients were included, of which 229 patients reached the week 54
endpoint at ﬁnal assessment. Patient characteristics are shown T1in
Table 1. Until week 54, CT-P13 treatment was stopped in 37
patients because of adverse events, in 11 patients because of
primary nonresponse, and in 27 patients because of loss of
response. Two CD and 2 UC patients were lost to follow-up
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(F1 Fig. 1). Dose optimization was performed in 17 and 16 of CD/
UC patients during the follow-up period.
Clinical Remission and Response Rates at
Weeks 14, 30, and 54
In CD, 49%, 53%, 48% and 86%, 81% and 65% of the
patients reached clinical remission and response by weeks 14, 30,
and 54, respectively (F2 Figs. 2A, 3A and 4A).
Stratifying patients with CD according to previous anti-
TNF exposure, 53.8%, 57%, and 53.5% of the anti–TNF-naive
patients reached clinical remission by weeks 14, 30, and 54,
whereas 91.1%, 85.9%, and 73.3% of the anti–TNF-naive patients
reached clinical response by weeks 14, 30, and 54, respectively.
In patients with a previous anti-TNF exposure, clinical remission
and response rates were 36.7%, 43.5%, and 32.4% and 67.3%,
67.4%, and 44.1% by weeks 14, 30, and 54, respectively (Figs.
TABLE 1. Baseline Disease Characteristics of Patients with IBD on Biosimilar IFX Therapy
CD (n ¼ 209) UC (n ¼ 144)
Sex (male/female) 99/110 74/70
Age at disease onset (median [IQR]; yr) 24 (19–34) 28 (22–39)
Disease duration (median [IQR]; yr) 5 (2–11) 5 (2–11)
Baseline disease activity (median [IQR]; points) CDAI: 319 (301–352; n ¼ 172) Mayo: 9 (7–11; n ¼ 136)
PDAI: 9 (5–11; n ¼ 77) pMayo: 7 (6–9; n ¼ 89)
Disease location (L1/L2/L3/L4/all L4; %) 16.3/31.1/41.1/1.5/8.3 —
Disease extent (E1/E2/E3; %) — 9.7/34.1/56.2
Disease behavior (B1/B2/B3; %) 56.5/21.0/22.5 —
Perianal disease (%) 39.2 —
Previous surgery (%) 21.5 —
Previous anti-TNF therapy (%) 23.4 (n ¼ 49) 19.4 (n ¼ 28)
IFX 18.2 (n ¼ 38) 12.5 (n ¼ 18)
Adalimumab 4.2 (n ¼ 9) 6.2 (n ¼ 9)
IFX + adalimumab 1 (n ¼ 2) 0.7 (n ¼ 1)
Concomitant steroid therapy (%) 42.6 64.6
Concomitant AZA therapy (%) 60.3 51.4
IQR, interquartile range; PDAI, Perianal Disease Activity Index.
FIGURE 1. Patients and follow-up.AU10 PNR, primary nonresponse; LOR, loss of response; AE, adverse event; 2 patients with CD and 2 patients with UC
were lost to follow-upAU11 .
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2B, 3B and 4B). Clinical response rates were signiﬁcantly differ-
ent at weeks 14, 30, and 54 (P, 0.01, P ¼ 0.005, and P ¼ 0.001,
respectively), whereas clinical remission rates were signiﬁcantly
different at weeks 14 and 54 (P ¼ 0.04 and P ¼ 0.02, respec-
tively) between anti–TNF-naive and anti–TNF-exposed patients
with CD.
In patients with UC, clinical remission and response rates
were 56%, 41%, and 43% and 74%, 66%, and 50% of the patients
by weeks 14, 30, and 54, respectively (Figs. 2A, 3A and 4A).
In anti–TNF-naive patients with UC, 59.5%, 45.7%, and
47.3% of the patients reached clinical remission by weeks 14, 30,
and 54 and 75%, 71.3%, and 51.4% of the patients reached clin-
ical response by weeks 14, 30, and 54, respectively. In patients
with UC with a previous anti-TNF exposure, 35.7%, 21.7%, and
26.5% of the patients reached clinical remission and 67.9%,
43.5%, and 42.1% of the patients reached clinical response by
weeks 14, 30, and 54, respectively (Figs. 2B, 3B and 4B). Clinical
response rates were signiﬁcantly different at week 30 (P ¼ 0.01),
whereas clinical remission rates were signiﬁcantly different at
weeks 14 and 30 (P ¼ 0.02 and P ¼ 0.04) between anti–TNF-
naive and previously anti–TNF-exposed patients with UC,
respectively.
Biochemical Response
In patients with CD, the mean CRP level signiﬁcantly
decreased between weeks 0 and 14 from 23.7 to 9.8 mg/L,
respectively (P , 0.001). The mean CRP levels were 9.4 and 9.6
mg/L at weeks 30 and 54, respectively (P , 0.001 and P ¼ 0.001
compared with baseline).
Trends were similar in UC. The mean CRP levels were
27.6, 8.7, 12.2, and 11.7 mg/L at weeks 0, 14, 30, and 54 with
a signiﬁcant decrease by weeks 14 (P , 0.001), 30 (P ¼ 0.002),
and 54 (P ¼ 0.009).
Therapeutic Drug Level Monitoring
In patients with CD, the mean biosimilar IFX TLs at weeks
2, 6, 14, 30, and 54 are presented in T2Table 2. Biosimilar IFX TLs
were signiﬁcantly lower in previously anti–TNF-exposed patients
at weeks 2 (P ¼ 0.03), 14 (P ¼ 0.02), and 30 (P ¼ 0.03) but not at
weeks 6 (P ¼ 0.148) and 54 (P ¼ 0.91) (Table 2).
In patients with UC, the mean biosimilar IFX TLs at weeks 2,
6, 14, 30, and 54 are presented also in Table 2. No signiﬁcant
difference was found in biosimilar IFX TLs between anti–TNF-naive
and previously exposed patients at any time points, with a trend
toward higher TLs in the anti–TNF-naive patient group (Table 2).
FIGURE 2. A, Clinical response and remission rates at week 14 in patients with IBD treated with the biosimilar IFX. B, Clinical response and
remission rates at week 14 in patients with IBD treated with the biosimilar IFX stratiﬁed by previous anti-TNF exposure; *P , 0.05.
FIGURE 3. A, Clinical response and remission rates at week 30 in patients with IBD treated with the biosimilar IFX. B, Clinical response and
remission rates at week 30 in patients with IBD treated with the biosimilar IFX stratiﬁed by previous anti-TNF exposure; *P , 0.05.
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Cumulative ADA positivity rates were 9.8% (26/266),
18.6% (58/312), 24.1% (70/290), and 33.8% (71/210) at weeks
0, 14, 30, and 54, respectively, in all patients with IBD. In
anti–TNF-naive patients with IBD, cumulative ADA positivity
rates were 4.3% (9/213), 12% (30/249), 20.9% (48/230), and
28.6% (50/175) at weeks 0, 14, 30, and 54, respectively. The
cumulative ADA positivity rates were signiﬁcantly higher at all
time points in anti–TNF-exposed patients 32% (17/53), 34.9%
(22/63), 36.6% (22/60), and 46.6% (21/45) at weeks 0, 14, 30,
and 54, respectively (P , 0.001 for all).
Cumulative ADA positivity rates in CD and UC patients
with and without previous anti-TNF exposure are presentedT3 in
Table 3. In CD, a signiﬁcant difference was found in ADA pos-
itivity rates between anti–TNF-naive and previously anti–TNF-
exposed patients at baseline (P , 0.001), weeks 14 (P ,
0.001), 30 (P ¼ 0.03), and 54 (P ¼ 0.03).
In UC, the difference was signiﬁcant in baseline ADA
positivity rates between anti–TNF-naive and previously anti–
TNF-exposed patients (P , 0.001), but this difference became
nonsigniﬁcant by week 14 and thereafter (week 14: P ¼ 0.14;
week 30: P ¼ 0.16; and week 54: P ¼ 0.27).
Concomitant azathioprine (AZA) prevented ADA forma-
tion at weeks 14 (6.5% versus 21.2%, P ¼ 0.01) 30 (12.7% versus
29.2%, P ¼ 0.02), and 54 (15% versus 45.2%, P ¼ 0.004) in
anti–TNF-naive but not in previously exposed patients with CD
(week 14: 40% versus 33.3%, P ¼ 0.75; week 30: 37.5% versus
38.5%, P ¼ 0.95; and week 54: 50% versus 50%, P ¼ 1.0).
By contrast, concomitant AZA did not prevent ADA
formation either in anti–TNF-naive (week 14: 19.2% versus
18.4%, P ¼ 0.91; week 30: 24% versus 22.4%, P ¼ 0.85; and
week 54: 29.3% versus 35%, P ¼ 0.58) or in previously exposed
patients with UC (week 14: 30% versus 36.4%, P ¼ 0.76; week
30: 40% versus 36.4%, P ¼ 0.86; and week 54: 40% versus 50%,
P ¼ 0.71).
Clinical efﬁcacy at week 14 or 30 was not affected by
concomitant AZA use in either patients with CD or UC (CD:
week 14 response: 87.2% versus 81.6%, P ¼ 0.28; week 14
remission: 52% versus 47.4%, P ¼ 0.52; week 30 response:
84.1% versus 76.8%, P ¼ 0.22; AU4and week 54 response: 69.1%
versus 56.9%, P ¼ 0.15; week 54 remission: 50.6% versus 39.2%,
P ¼ 0.2; UC: week 14 response: 73% versus 74.3%, P ¼ 0.85;
week 14 remission: 52.7% versus 57.1%, P ¼ 0.59; week 30
FIGURE 4. A, Clinical response and remission rates at week 54 in patients with IBD treated with the biosimilar IFX. B, Clinical response and
remission rates at week 54 in patients with IBD treated with the biosimilar IFX stratiﬁed by previous anti-TNF exposure; *P , 0.05.
TABLE 2. Mean TLs in Patients with IBD on Biosimilar IFX Therapy
Week 2, mg/mL Week 6, mg/mL Week 14, mg/mL Week 30, mg/mL Week 54, mg/mL
CD
Mean biosimilar IFX TLs 18.9 (n ¼ 85) 17.3 (n ¼ 74) 6.1 (n ¼ 136) 4.3 (n ¼ 119) 5.3 (n ¼ 53)
Without previous anti-TNF 20.4a 16.5 6.5a 4.6a 5.4
With previous anti-TNF 11.7a 10.7 3.7a 2.1a 5.0
UC
Mean biosimilar IFX TLs 19.0 (n ¼ 67) 11.8 (n ¼ 50) 4.9 (n ¼ 97) 3.9 (n ¼ 63) 4.5 (n ¼ 39)
Without previous anti-TNF 20.6 12.9 4.9 4.0 4.9
With previous anti-TNF 9.9 5.7 4.8 3.3 1.9
aMean biosimilar IFX TLs differed signiﬁcantly between anti–TNF-naive and previously anti–TNF-exposed patients at week 2 (P ¼ 0.03), at week 14 (P ¼ 0.02), and at week 30 (P ¼
0.03) in CD.
Inﬂamm Bowel Dis  Volume 00, Number 00, Month 2017 Biosimilar Inﬂiximab in IBD
www.ibdjournal.org | 5
Copyright © 2017 Crohn’s & Colitis Foundation. Unauthorized reproduction of this article is prohibited.
response: 65.6% versus 66.1%, P ¼ 0.95; week 30 remission:
41% versus 41.1%, P ¼ 0.99; and week 54 response: 48% versus
51.2%, P ¼ 0.76; week 54 remission: 40% versus 46.5%, P ¼
0.53). Of note, the clinical remission rates were signiﬁcantly dif-
ferent in CD at week 30 (63.7% versus 40.6%, P ¼ 0.002) and
clinical response at week 30 in previously exposed patients with
CD (80.8% versus 44.4%, P ¼ 0.01).
Adverse Events
At week 54, the cumulative rate of adverse events was
24%. Infusion reactions occurred in 31 (8.8%) patients. Sixteen of
31 patients previously received anti-TNF therapy. Infections
occurred in 32 (9%) patients with no cases of tuberculosis. One
patient developed invasive fungal sepsis, resulting in death. No
cases of malignancy occurred during follow-up of the cohort.
Detailed adverse event data are presented inT4 Table 4.
DISCUSSION
In the present prospective, multicenter, nationwide study of
patients with IBD treated with the biosimilar IFX, clinical
remission and response rates were maintained throughout 54
weeks and were in line with the previously published data on the
originator product or CT-P13 biosimilar. In addition, previous
anti-TNF exposure affected clinical efﬁcacy, whereas parallel
AZA was effective in preventing ADA formation in anti–TNF-
naive patients.
The efﬁcacy of maintenance IFX therapy in active CD was
demonstrated in the ACCENT I trial, where clinical remission
rates at week 30 were signiﬁcantly higher in week 2 responder
patients receiving IFX 5 mg/kg and 10 mg/kg compared with the
placebo group (39% and 45% versus 21%), and the difference
between the treatment groups remained signiﬁcant also at week
54.21 In a retrospective Hungarian study, the overall response rate
was 86.2% (313 of 363 patients), and the overall remission rate
was 46% (167 of 363 patients) at the end of induction therapy
with the originator IFX in patients with CD.22 In addition, in the
ACT 1 trial, clinical response and remission rates at week 54 were
45.5% and 34.7%, respectively, in patients with UC receiving 5
mg of IFX compared with 19.8% and 16.5% in the placebo
group.18
Clinical response, remission rates, and safety data23 in the
present cohort were in line with the above ﬁndings and with data
presented in real-life cohorts treated with IFX. In the retrospective
study by Jung et al, clinical response and remission were achieved
by 87.5% and 75% of the anti–TNF-naive patients with CD and
100% and 50% of the anti–TNF-naive patients with UC at week
54, respectively.5 In a Norwegian single-center study, 34 (79%)
patients with CD achieved a Harvey–Bradshaw score of #4, and
18 (56%) patients with UC achieved a pMayo score of #2 at
week 14. In addition, the mean serum CRP levels signiﬁcantly
decreased from baseline to week 14 both in CD (22.5 versus 4.9
mg/L, P ¼ 0.006) and UC (36.8 versus 9.6 mg/L, P ¼ 0.012).6
TABLE 3. Cumulative ADA Positivity in Patients with IBD on Biosimilar IFX Therapy
ADA Positivity at Baseline ADA Positivity at Week 14 ADA Positivity at Week 30 ADA Positivity at Week 54
CD 15/169 (8.9%) 32/190 (16.8%) 39/170 (22.9%) 38/124 (30.6%)
Without previous anti-TNF 5/134 (3.7%)a 17/148 (11.5%)a 25/131 (19.1%)a 24/94 (25.5%)a
With previous anti-TNF 10/35 (28.6%)a 15/42 (35.7%)a 14/39 (35.9%)a 14/30 (46.7%)a
UC 11/97 (11.3%) 26/122 (21.3%) 31/120 (25.8%) 33/96 (34.4%)
Without previous anti-TNFa 4/79 (5.1%)a 13/101 (18.8%) 23/99 (23.2%) 26/81 (32.1%)
With previous anti-TNF 7/18 (38.9%)a 7/21 (33.3%) 8/21 (38.1%) 7/15 (46.7%)
aADA positivity rates differed signiﬁcantly between anti–TNF-naive and previously anti–TNF-exposed patients at baseline (P , 0.001), at week 14 (P , 0.001), at week 30 (P ¼ 0.03),
and at week 54 (P ¼ 0.03) in CD and at baseline (P , 0.001) in UC.
TABLE 4. Adverse Events in Patients with IBD on
Biosimilar IFX Therapy
Adverse Event Patients (%)
Mortality 1 (0.3)
Infections
Upper respiratory tract infection 9 (2.5)
Gastroenteritis 10 (2.8)
Viral infections (inﬂuenza, herpes, varicella) 7 (2)
Clostridium difﬁcile colitis 3 (0.8)
Invasive fungal infection 1 (0.3)
Pneumonia 1 (0.3)
Urinary tract infection 1 (0.3)
Tuberculosis 0 (0)
Allergy
Infusion reaction 31 (8.8)
Anaphylaxis 1 (0.3)
Others
Arthralgia 11 (3.1)
Delayed hypersensitivity 10 (2.8)
Malignancy 0 (0)
Gonczi et al Inﬂamm Bowel Dis  Volume 00, Number 00, Month 2017
6 | www.ibdjournal.org
Copyright © 2017 Crohn’s & Colitis Foundation. Unauthorized reproduction of this article is prohibited.
High early clinical remission and response rates were found in the
previous publication from the present cohort in 210 patients with
IBD throughout 30 weeks. Clinical response and remission rates
at week 14 were 81 and 54% in CD and 78 and 59% in UC,
respectively. At week 30, steroid-free clinical remission was
achieved in 50% of the patients with CD and 56% of the patients
with UC.7 In a Czech study including 52 patients, clinical
response ($70 point decrease in CDAI score from baseline in CD
and $2 point decrease in pMayo score from baseline) and
remission rates (CDAI ,150 in CD and total score on partial
Mayo Score index #2 points) at week 14 were 50% and 50% in
CD and 54.4% and 40.9% in UC, respectively.9
We observed a cumulative adverse event rate of 24% in the
present cohort. The rate of infusion reactions was 8.8%, of which
approximately half of the patients were previously exposed to the
originator anti-TNF therapy. The rate of infections (9%) is in line
with published data on biosimilar or originator IFX. Of note, no
cases of tuberculosis were identiﬁed during follow-up.7 In the
study by Keil et al including 52 patients, 4 adverse events
occurred during the 14-weeks follow-up period, including allergic
reaction, phlebothrombosis of the lower extremity, pneumonia,
and herpes labialis.9 Balint et al investigated the incidence and
characteristics of infusion reactions in 384 patients from 13 Hun-
garian and 1 Czech IBD centers. The rate of infusion reactions
was 7.2% (21 patients) among Hungarian patients and 13 patients
of those received previous anti-TNF therapy.24
In this study, ADA positivity rates were signiﬁcantly higher
in patients with previous exposure of anti-TNF therapy through-
out week 54 in CD, but this difference was nonsigniﬁcant after
week 14 in UC. In addition, signiﬁcantly lower early IFX TLs
were observed in patients previously exposed to IFX, compared
with naive patients. Farkas et al reported signiﬁcantly higher IFX
TLs in patients with UC with mucosal healing or steroid-free
mucosal healing compared with patients without mucosal healing
at week 14.8 In a Norwegian single-center study, 4 CD and 4
patients with UC had an IFX TL of 0 mg/L, and 3 of them
received anti-TNF therapy previously. Two of these patients
had high ($80 AU/L), 5 had medium/high (,80 AU/L), and 1
had low ADA levels (,10 AU/L).6 ADA and TL data are awaited
from the international crossover study from patients with CD
treated with originator or biosimilar IFX.25,26
Parallel AZA was effective in preventing ADA formation in
anti–TNF-naive CD but not patients with UC. Similarly, lower rates
of antibodies against IFX were reported by Baert et al in patients
with CD taking immunosuppressives compared with patients without
immunosuppressive use during IFX therapy (43% versus 75%, P ,
0.01).27 Vermeire et al studied the rate of ATIAU5 formation in a multi-
center cohort of patients with CD receiving methotrexate and IFX,
AZA, and IFX or IFX alone. Lower ATI formation was observed in
patients with CD receiving methotrexate or AZA compared with
those receiving IFX alone (46% versus 73%, P , 0.001).28
Strengths of this study are the prospective study design and
the harmonized, standardized follow-up and monitoring strategy
in all participating centers. A limitation of our study is that
mucosal healing was not systematically evaluated. Furthermore,
our cohort includes patients with previous drug exposure and drug
holiday, but not switch.
In conclusion, in the present multicenter, nationwide cohort
including a large cohort of patients with IBD treated with
biosimilar IFX, the efﬁcacy, safety, and immunogenicity of the
biosimilar IFX were comparable with those of the originator
compound reported in previous studies. Data on immunogenicity
and drug TLs obtained in this study support the routine use of
therapeutic drug level monitoring in patients treated with
biosimilar IFX. In addition, parallel AZA was effective in
preventing ADA formation in anti–TNF-naive patients, while pre-
vious anti-TNF exposure affected clinical efﬁcacy.
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